U.S. RESEARCH ROUNDUP-American Express, Capricor …

Oct 20, 2024 · Wall Street analysts have revised ratings and price targets for several U.S. companies. Notable changes include TD Cowen raising the target price for American Express, …

97%
OFF

Deep Dive Into Capricor Therapeutics Stock: Analyst ... - Nasdaq

2 weeks from now

Sep 20, 2024 · Net Margin: Capricor Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -276.97%, the company demonstrates strong profitability and …

nasdaq.com

FAQs about U.S. RESEARCH ROUNDUP-American Express, Capricor … Coupon?

Who is capricor Therapeutics?

Capricor Therapeutics is a biotechnology company offering a new approach on drug development in Duchenne muscular dystrophy and beyond. We are patient-focused first, while advancing precision medicine. ...

What does capricor do?

Capricor’s science is focused on cell and exosome-based biology, offering multiple modalities allowing us to create a new class of therapeutic medicines for patients. Sign up today and receive company updates to your inbox. © 2024 Capricor Therapeutics, Inc. ...

What is capricor's next-generation therapeutic platform?

Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s current focus is on developing exosomes capable of delivering nucleic acids as well as proteins to treat or prevent a variety of diseases. ...

What is capricor's lead product candidate?

Capricor’s lead product candidate, deramiocel (CAP-1002), is an allogeneic cell therapy that is currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Deramiocel is comprised of allogeneic cardiosphere-derived cells, or CDCs. ...

What is capricor cap 1002?

Capricor’s lead candidate, deramiocel (CAP-1002), is an allogeneic cell therapy that is currently in Phase 3 clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. ...

Is American Express a good stock to buy now?

Five years ago, shares of American Express traded at a price-to-earnings (P/E) ratio of 16. Thanks to the stock's impressive run, it can now be purchased for a P/E multiple of just under 22. Seeing a 37% rise in the valuation makes sense, given the company's strong financial performance and the overall market's historically high returns. ...